Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)

Fig. 2

CircRNA CDR1as positively regulated HOXA9 in DDP-sensitive NSCLC cells by sponging miR-641. The online starBase software (http://starbase.sysu.edu.cn/) predicted the binding sites of miR-641 with a circRNA CDR1as and d 3′ UTR regions of HOXA9 mRNA. Dual-luciferase reporter gene system validated the targeting sites of miR-641 with b circRNA CDR1as and e 3′ UTR regions of HOXA9 mRNA. RNA pull-down assay results indicated that miR-641 could be enriched by c circRNA CDR1as and f HOXA9 mRNA probes, respectively. g CircRNA CDR1as was successfully silenced and overexpressed in DDP-sensitive NSCLC cells, determined by Real-Time qPCR. CircRNA CDR1as negatively regulated the levels of h miR-641 and positively regulated i HOXA9 mRNA in NSCLC cells. j, k Western Blot analysis revealed that circRNA CDR1as inhibited HOXA9 protein levels in NSCLC cells by targeting miR-641. Each experiment repeated at least 3 times. **P < 0.01. “NS” represented no statistical significance

Back to article page